Merck's SWOT analysis: stock faces keytruda patent cliff, gardasil challenges

Merck (MRK) reported strong Q4 2024 results, exceeding revenue and EPS expectations, but its 2025 guidance fell below Street estimates, primarily due to a significant, temporary halt in Gardasil vaccine sales in China through mid-2025. While blockbuster Keytruda maintains robust performance, the company faces a projected revenue gap from its 2028 loss of exclusivity, which it is actively addressing through pipeline development and strategic acquisitions like Verona Pharma, signaling a critical period for management to demonstrate a clear path for sustained growth.

Analysis

Merck & Co. (MRK) presents a mixed investment profile, characterized by strong recent performance overshadowed by significant near-term and long-term risks. The company surpassed Q4 2024 expectations with a 1% revenue and 7% EPS beat, driven by the continued outperformance of its blockbuster drug Keytruda, which exceeded consensus sales by 3% to reach $7.84 billion. However, this strength is offset by a cautious 2025 outlook, with revenue and EPS guidance falling 3% and 2.2% below Street expectations, respectively. This downward revision is directly attributable to a temporary but impactful pause in Gardasil vaccine sales in China through mid-2025, a measure taken to address high inventory levels at its distribution partner. This single issue has caused analysts to slash 2025 China Gardasil sales forecasts from $2 billion to between $0 and $1 billion. The paramount long-term challenge remains the 2028 loss of exclusivity (LOE) for Keytruda, which is projected to cause a 10-20% sales decline post-LOE. Management's strategy to bridge this revenue gap hinges on aggressive business development, including a stated appetite for acquisitions in the $1-15 billion range and the recent $10 billion purchase of Verona, whose COPD drug Ohtuvayre holds a $3-4 billion peak sales potential. While the internal pipeline contains promising assets, their commercial scaling is not anticipated until after 2025, highlighting the critical importance of M&A execution to de-risk the post-2028 profile.

Key Decisions for Investors

• Investors should closely monitor management's upcoming communications for a clear resolution plan and timeline regarding the Gardasil inventory issues in China, as this is the primary overhang on 2025 performance and near-term sentiment.
• The central long-term thesis rests on Merck's ability to execute its M&A strategy to offset the 2028 Keytruda patent cliff; therefore, evaluating the success of the Verona integration and watching for further value-accretive deals is critical.
• Given the disconnect between strong current profitability and future revenue uncertainty, positions should be weighed against the significant execution risk in both the pipeline and M&A, as any setbacks could negate the stock's apparently undervalued status.